+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2



BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2



American Journal of Human Genetics 60(5): 1031-1040



In order to evaluate the role of inherited BRCA2 mutations in American families--particularly the appearance in America of European founder mutations--the BRCA2 coding sequence, 5' UTR, and 3' UTR were screened in 22 Caucasian American kindreds with four or more cases of breast or ovarian cancer. Six mutations were found that cause a premature-termination codon; four of them have been reported elsewhere, and two are novel. In the four families with previously seen mutations, the distinct lineages at high risk of cancer were of Dutch, German, Irish, and Ashkenazi Jewish ancestry; mutations in Europe reflect these ancestries. The families with novel mutations were Puerto Rican Hispanic (exon 9 deletion 995delCAAAT) and Ashkenazi Jewish (exon 11 deletion 6425delTT). Among female BRCA2-mutation carriers, risks of breast cancer were 32% by age 50 years, 67% by age 70 years, and 80% by age 90 years, yielding a lifetime risk similar to that for BRCA1 but an older distribution of ages at onset. BRCA2 families also included multiple cases of cancers of the male breast (six cases), ovary (three cases), fallopian tube (two cases), pancreas (three cases), bladder (two cases), and prostate (two cases). Among 17 Ashkenazi Jewish families with four or more breast or ovarian cancers, 9 families (including 3 with ovarian cancer and 1 with male breast cancer) carried none of the three ancient mutations in BRCA1 or BRCA2. To date, both BRCA2 and BRCA1 have been screened by SSCA, supplemented by the protein-truncation test, in 48 families with four or more breast or ovarian cancers. Mutations have been detected in BRCA1 in 33 families, in BRCA2 in 6 families, and in neither gene in 9 families, suggesting both the probable cryptic nature of some mutations and the likelihood of at least one other BRCA gene.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008209803

Download citation: RISBibTeXText

PMID: 9150150


Related references

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. American Journal of Human Genetics 60(5): 1059-1067, 1997

High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. Human Mutation 16(6): 482-490, 2000

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Research and Treatment 124(3): 643-651, 2011

Selective genetic screening in 250 Belgian breast and ovarian cancer families identifies BRCA1 or BRCA2 mutations in 20% of cases. European Journal of Human Genetics 10(Supplement 1): 84, 2002

High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families. Familial Cancer 13(4): 603-609, 2015

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clinical Cancer Research 6(3): 782-789, 2000

Identification of breast-ovarian cancer families without BRCA1 or BRCA2 mutations. American Journal of Human Genetics 65(4): A328, 1999

Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia. Gene 498(2): 169-176, 2012

BRCA1 and BRCA2 analysis in breast cancer families from Sardinia Identification of two BRCA2 founder mutations with their clinical and pathological implications. European Journal of Cancer 37(Supplement 6): S176, 2001

BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1. British Journal of Cancer 78(11): 1417-1420, 1998

Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online. Human Mutation 13(3): 256, 1999

Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations. South African Medical Journal 100(2): 113-117, 2010

BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer. Genetic Testing 1(1): 41-46, 1997

BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer. European Journal of Cancer Prevention 7 Suppl 1: S3-S5, 2000

BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer. European Journal of Cancer Prevention 7: S3-S6, 1998